From voltage-gated calcium channel pharmacology to real-world prescribing patterns, NNPRC bridges the gap between bench science and bedside practice in the management of neuropathic pain syndromes.
Neuropathic pain is not simply "pain that hurts more." It is a distinct pathophysiological entity — one arising from lesions or disease within the somatosensory nervous system itself, driving aberrant signal generation, maladaptive synaptic plasticity, and a cascade of inflammatory mediators that conventional analgesics are poorly equipped to interrupt. Roughly 7–10% of the general population carries a diagnosis of neuropathic pain; among patients with diabetes, HIV, or post-herpetic sequelae, that figure climbs dramatically.
NNPRC was established in 1998 with a singular mandate: to produce rigorous, reproducible science that actually translates to patient outcomes. Our laboratory investigations focus on the α2δ subunit of voltage-gated calcium channels — the molecular target through which gabapentinoids exert their analgesic, anticonvulsant, and anxiolytic effects. Understanding the binding kinetics of gabapentin at the α2δ-1 and α2δ-2 receptor subtypes is not academic trivia. It determines dosing strategy, predicts inter-patient variability, and explains why some patients achieve robust analgesia at 300 mg three times daily while others require titration to 3,600 mg before experiencing meaningful relief.
What makes neuropathic pain such a treacherous target? Central sensitization. Once the dorsal horn neurons undergo wind-up — a state of hyperexcitability driven by repeated nociceptive input and facilitated by glutamatergic NMDA receptor activation — conventional opioid pathways provide diminishing returns. Gabapentin's mechanism sidesteps this bottleneck, but not without nuance. Its oral bioavailability is dose-dependent and saturable: at 300 mg, absorption approximates 60%; at 1,600 mg per dose, that figure drops to below 35%. This non-linear pharmacokinetic profile has profound implications for how clinicians should structure escalation schedules.
Our research doesn't stop at the receptor. We track real-world prescribing data, post-market surveillance signals, and patient-reported outcomes across 14 affiliated clinical sites spanning California, Oregon, and New York. When the FDA updated its MedWatch guidance on gabapentin-related respiratory depression in 2019, NNPRC's longitudinal cohort data contributed to the epidemiological evidence base. That's the kind of translational science we exist to do.
Characterizing the absorption, distribution, metabolism, and excretion (ADME) profile of gabapentin across diverse patient populations, including those with renal impairment where creatinine clearance directly governs dose adjustments.
Read research →Systematic comparison of Neurontin (brand) and FDA-approved generic gabapentin formulations using area-under-the-curve (AUC) and peak plasma concentration (Cmax) as primary endpoints across multiple dissolution media.
Read research →Prospective cohort surveillance of gabapentin use in anxiety disorders, restless leg syndrome, and alcohol withdrawal, with patient-reported outcome measures (PROMs) anchored to validated neuropathic pain scales.
Read research →Investigating the public health risks posed by counterfeit and unapproved pharmaceutical sources, with a focus on educating patients on identifying DEA-registered, NABP-accredited dispensing channels.
Read research →Exploring glial cell activation, neuroinflammation, and dorsal horn wind-up as targets for pharmacological intervention beyond first-line gabapentinoid therapy, including combination strategies.
Read research →Translating bench findings into evidence-based prescribing recommendations aligned with AAN, IASP, and CDC frameworks — with a specific emphasis on risk stratification in elderly and renally-compromised populations.
Read research →A dual-boarded neurologist and clinical pharmacologist, Dr. Thorne has authored over 90 peer-reviewed papers on gabapentinoid mechanisms and neuropathic pain. He trained at Johns Hopkins and completed his post-doctoral fellowship at the UCSF Pain Management Center before founding NNPRC's translational research division in 2003.
View Full Biography